# AUTOTAC Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/autotac-bio

- Industry: Healthcare IT
- Headquarters: Seoul, South Korea
- Website: www.autotacbio.com
- Total disclosed funding: $17M
- Latest round: Series B (Apr 9, 2020)
- Investors on record: 10

## About

Based in Seoul, South Korea, and founded in 2018, AUTOTECH Bio is a pharmaceutical company that focuses on the development of protein target decomposition platform technology. The company's CEO Yong Tae Kwon graduated from Seoul National University and was a senior scientist at the California Institute of Technology.

The company provides innovative drug platforms based on targeted protein degradation using autophagy in the human body. It can be applied to various cancers, degenerative brain diseases, autoimmune and metabolic diseases, and rare and incurable diseases. The company's pipelines include neurodegeneration, amyloidosis, cancer, muscular dystrophy, infectious disease, and metabolic disease.

## Funding rounds

- Series B, Apr 9, 2020, $17M — AJU IB Investment, Shinhan Venture Investment, Mirae Asset Capital, Daekyo Investment, Mirae Asset Venture Investment, LSK Investment, KNet Investment Partners, DAYLI Partners, DS Asset Management, ILJIN SNT

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series B
- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series B
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series B
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series B
- KNet Investment Partners (https://capitalatlas.ai/funds/knet-investment-partners) — Series B
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series B
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series B
- ILJIN SNT — Series B